Intimation about the closure of trading window for Q ended 31st December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sandu Pharmaceuticals has informed the BSE that the trading window for dealing in its shares will remain closed from Thursday, 1 January 2026 until 48 hours after the company declares its unaudited financial results for the quarter ended 31 December 2025. This restriction applies to Directors, Key Managerial Personnel, Promoters, Promoters Group, Designated Persons, and their immediate relatives, as required under SEBI's Insider Trading Regulations. The date of the board meeting to approve the Q3 results has not yet been announced and will be communicated separately. This is a routine compliance intimation, not indicative of any insider transaction.
No direct impact on shareholders or stock price. This is a standard regulatory disclosure ahead of quarterly results — it simply means insiders cannot trade until results are published, which helps ensure fair disclosure.